Comparative Pharmacology
Head-to-head clinical analysis: ERYC versus ERYTHRA DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC versus ERYTHRA DERM.
ERYC vs ERYTHRA-DERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. It also exhibits anti-inflammatory and immunomodulatory effects, reducing neutrophil chemotaxis and bacterial lipase production.
250-500 mg orally every 6 hours or 333-500 mg orally every 8 hours; maximum 4 g/day.
Apply a thin layer to the affected area(s) twice daily. For topical use only. Adult dose is 2% solution or ointment.
None Documented
None Documented
2–4 hours in adults with normal renal function; prolonged to 4–8 hours in severe hepatic impairment; does not significantly change in renal failure.
Terminal elimination half-life of 2-4 hours; prolonged to 5-6 hours in hepatic impairment.
Primarily biliary excretion of unchanged drug (60–80%); renal excretion accounts for 10–15% of an oral dose, with minimal fecal elimination (<5%).
Primarily biliary fecal elimination (60-70%); renal excretion of unchanged drug <15%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic